A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (300 mg) in adUlt subjects with moderate to seveRE plaque psoriasis – ALLURE - ALLURE

ovartis Pharma Services AG0 个研究点目标入组 210 人开始时间: 2016年7月29日最近更新: 2018年7月23日

适应症

试验速览

暂无简介。

•* Men or women of at least 18 years of age at the time of Screening.
•* Moderate to severe chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
•* Candidate for systemic therapy.
•* Additional inclusion criteria may apply , please refer to the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 189
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 21

•* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis)
•* Ongoing use of prohibited treatments.
•* Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
•* Pregnant or nursing (lactating) women
•*Additional exclusion criteria may apply , please refer to the protocol.

发起方